Literature DB >> 1562285

Mechanisms of inactivation of Schistosoma mansoni and mammalian glutathione S-transferase activity by the antischistosomal drug oltipraz.

B Nare1, J M Smith, R K Prichard.   

Abstract

Glutathione S-transferase (GST) purified from Schistosoma mansoni or human placenta was inhibited by the antischistosomal drug oltipraz (OPZ) in a time- and concentration-dependent manner. Inhibition of placenta GST was complete at a low concentration of drug, whereas that of parasite GST was incomplete and relatively high amounts of OPZ were needed to reach 50% inhibition. Complete reactivation of GST from placenta was achieved with dithiothreitol (DTT) and other sulfhydryl-containing compounds, while the inactivation of parasite GST was irreversible. The oxy-derivative of OPZ (RP 36,642), in which the thione sulfur is replaced with oxygen, did not inhibit GST activity. There were no differences between OPZ and RP 36,642 in their patterns of binding to the hydrophobic non-substrate site of GST. GST from the placenta incorporated much higher levels of [14C]N-ethylmaleimide compared to schistosome GST. The incorporation of [14C]N-ethylmaleimide by GST was inhibited by OPZ but not by RP 36,642. Yeast and S. mansoni hexokinases were similarly inhibited by OPZ but not by RP 36,642. Both hexokinase preparations recovered their activity following incubation with DTT. These data suggest that the inactivation of these enzymes by OPZ is a result of its interaction with their SH groups. Thus, the antischistosomal activity of OPZ may be accounted for by its interaction with the SH groups of macromolecules in general.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1562285     DOI: 10.1016/0006-2952(92)90512-h

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  The redox biology of schistosome parasites and applications for drug development.

Authors:  Hsin-Hung Huang; Coraline Rigouin; David L Williams
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators.

Authors:  Debasis Mondal; Devin Narwani; Shahnawaz Notta; Dawood Ghaffar; Nikhil Mardhekar; Syed S A Quadri
Journal:  Cancer Drug Resist       Date:  2021-03-19

3.  Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication.

Authors:  H J Prochaska; Y Yeh; P Baron; B Polsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

Review 4.  The role of glutathione-S-transferase in anti-cancer drug resistance.

Authors:  Danyelle M Townsend; Kenneth D Tew
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 5.  High-content approaches to anthelmintic drug screening.

Authors:  Mostafa Zamanian; John D Chan
Journal:  Trends Parasitol       Date:  2021-06-03

6.  Comparative effectiveness of 4 natural and chemical activators of Nrf2 on inflammation, oxidative stress, macrophage polarization, and bactericidal activity in an in vitro macrophage infection model.

Authors:  Malika Ali; Marcel Bonay; Valentin Vanhee; Stéphane Vinit; Therese B Deramaudt
Journal:  PLoS One       Date:  2020-06-08       Impact factor: 3.240

7.  PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs?

Authors:  Raphael Taiwo Aruleba; Tayo Alex Adekiya; Babatunji Emmanuel Oyinloye; Priscilla Masamba; Londiwe Simphiwe Mbatha; Ashley Pretorius; Abidemi Paul Kappo
Journal:  Infect Disord Drug Targets       Date:  2019

Review 8.  A Review of Nanotechnology for Targeted Anti-schistosomal Therapy.

Authors:  Tayo Alex Adekiya; Pierre P D Kondiah; Yahya E Choonara; Pradeep Kumar; Viness Pillay
Journal:  Front Bioeng Biotechnol       Date:  2020-01-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.